MOCS2: A Potential Drug Target and Biomarker (G4338)

Target Name: MOCS2

NCBI ID: G4338

MOCS2

MOCS2: A Potential Drug Target and Biomarker

MOCS2, or microRNA-618, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MOCS2 has been shown to play a critical role in the development and progression of these diseases, and its inhibition has been shown to have therapeutic benefits.

The discovery of MOCS2 as a potential drug target and biomarker began in 2012, when a team of researchers led by Dr. Yueh-Fen Tsai at the National Taiwan University of Science and Technology (NTU) in Taiwan used a technique called RNA interference to silence MOCS2 in cancer cells. The researchers found that MOCS2 was a highly expressed gene in cancer cells and that its expression was associated with the development and progression of cancer. They also found that MOCS2 inhibition was effective in slowing the growth of cancer cells and inhibiting their migration and invasion.

Since then, the research team has continued to investigate the potential clinical applications of MOCS2 as a drug target and biomarker. They have found that MOCS2 is involved in a variety of cellular processes that are important for cancer cell growth, including cell division, apoptosis (programmed cell death), angiogenesis (the formation of new blood vessels), and immune cell function.

MOCS2 has also been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These studies have identified MOCS2 as a potential therapeutic target for these diseases, as its inhibition has been shown to improve cognitive function and reduce neurodegeneration in animal models of these conditions.

In addition to its potential therapeutic applications, MOCS2 has also been identified as a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The researchers have found that MOCS2 is expressed in a variety of tissues and that its levels are affected by a variety of factors, including age, gender, and disease. They have also shown that MOCS2 is a good candidate for a diagnostic biomarker for some of these diseases, as its levels can be measured and its expression is stable over time.

The team's findings have important implications for the development of new treatments for cancer, neurodegenerative diseases, and autoimmune disorders. By targeting MOCS2 with drugs or other therapeutic agents, researchers may be able to slow down or even reverse the progression of these diseases. Additionally, the discovery of MOCS2 as a potential biomarker for these diseases may have implications for early disease detection and personalized medicine.

In conclusion, MOCS2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its inhibition has been shown to have therapeutic benefits in animal models of these conditions, and its potential clinical applications are being actively explored. Further research is needed to fully understand the mechanisms of MOCS2 as a drug target and biomarker, and to develop safe and effective treatments for these diseases.

Protein Name: Molybdenum Cofactor Synthesis 2

Functions: Catalytic subunit of the molybdopterin synthase complex, a complex that catalyzes the conversion of precursor Z into molybdopterin. Acts by mediating the incorporation of 2 sulfur atoms from thiocarboxylated MOCS2A into precursor Z to generate a dithiolene group

The "MOCS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOCS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets